SFEBES2026 Poster Presentations Thyroid (34 abstracts)
Graves’ disease: prospective 10 year outcomes for 100 consecutive individuals at a single centre
Muhammad Muneeb Ibad 1 , Mrinalini Srichandran 1 , Sangeeth Veluchamy 1 , Waseem Majeed 1 , Natalie Gallant 1 , Sarah Jamil 1 , Rupinder Kochhar 1 , Suhani Bahl 2 , Lakdasa Premawardhana 2 , Peter Taylor 2 , Onyebuchi Okosieme 2 , Colin Dayan 2 & Adrian Heald 3
1Salford Royal Hospital, Salford, United Kingdom; 2Cardiff University School of Medicine, Cardiff, United Kingdom; 3The School of Medicine and Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Introduction: The prevalence of Graves’ disease is approximately 1%. We undertook an evaluation of outcomes for 100 people diagnosed with Graves’ disease over a 10-year period.
Methods: All individuals were seen in the endocrinology outpatient clinic as consecutive presentations at a single UK centre. Individuals were first seen between 2012 and 2014. Individuals were first seen between 2012 and 2014.
Results: Of the 100 consecutive patients, 15 were male and 85 were female. The median age at diagnosis was 39.5 years(Interquartile Range(IQR):31-52) with median 43 years (IQR:31-61) for males and 39 years (IQR:31-51) for females. Eighty-seven individuals received carbimazole in the first year. 8 people were started on propylthiouracil, 3 did not receive any medical treatment while 2 received both propylthiouracil and carbimazole. Distribution of FT4 at baseline was skewed: median FT4 29.3pmol/l falling to 10-year median 16.2 pmol/l (Gaussian distribution). TSH was suppressed at baseline. TSH levels increased up to 5-year(1.10 mU/l); 10-year follow-up(1.15 mU/l). Over time, 25% continued to exhibit low/suppressed TSH levels, while 9% had elevated TSH levels. Overall, 37% individuals relapsed, 24% post-radioactive-iodine. For those who relapsed the median age at diagnosis was 34years (IQR:30-53) vs no relapse at 42years (IQR:32-52). At last/10-year follow-up 39% were euthyroid and not on therapy 22% remained on pharmacotherapy alone, 12% had undergone thyroid surgery, radioactive iodine alone 13% with combination treatment for 7%. 7% had died. Thyroid eye disease affected 26.7%males and 24.7%females. Baseline TRAb showed positive correlation with baseline FT4(Spearman’s rho=0.284, P = 0.004), with no significant association between baseline TRAb and relapse likelihood
Conclusion: Only about one third of patients remained in remission off anti-thyroid treatment, with a further one third requiring definitive treatment with thyroidectomy or radioactive iodine, demonstrating the potential for immunomodulatory therapy deployment in the future.
Volume 117
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2026 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more